BOVINE IGG AND HUMAN IMMUNOLOGIC RESPONSES & DISEASES
Project Number5R01AI024005-02
Contact PI/Project LeaderKULCZYCKI, ANTHONY
Awardee OrganizationWASHINGTON UNIVERSITY
Description
Abstract Text
Bovine milk IgG, the major xenogeneic immunoglobulin found in the human
diet (often 500 mg/day), is sometimes significantly absorbed in humans and
selectively found in human breast milk. Bovine milk IgG has an unusual
specificity pattern for some human FcGamma receptors and has
immunomodulatory properties in vitro. Our major aim is to test a
hypothesis (consistent with epidemiologic data) that dietary bovine IgG,
possibly in conjunction with human antibodies, may significantly influence
human responses in vivo and may play a role in the pathogenesis of some
human immunologic diseases. We plan: (1) To study mechanisms by which
bovine milk IgG inhibits antibody secretion from pokeweed mitogen
stimulated human peripheral blood mononuclear cells in vitro, and B cell
maturation pathway sites of inhibition. Human mononuclear cells will be
cultured with bovine IgG preparations to characterize the subclass region,
and aggregate size of IgG and the cell types involved in the observed
inhibition. To evaluate effects of bovine IgG on spontaneous antibody
secretion, mitogenesis, MLR, and cytotoxicity. (2) To examine bovine milk
IgG inhibition of mouse plaque-forming cell (PFC) responses in vitro with
studies not possible in the human system. To evaluate effects of in vivo
and in vitro exposure of mouse cells on LPS-induced and antigen-specific
PFC responses, to compare inhibitory effects of bovine, human and mouse IgG
subclasses, to examine mechanisms of inhibition and possible suppressor
cells and/or factors. (3) To measure bovine IgG levels and molecular size
of bovine IgG-containing fractions in human breast milk in mothers of
normal infants and mothers of infants with colic. To study proteolysis,
absorption, cellular association, transplacental and transmammary passage,
and serum half-life of bovine IgG in humans and animal models. (4) To
determine whether bovine IgG exposures, serum levels of bovine IgG, or
antibodies to bovine IgG are related to the occurrence and severity of
infantile colic, of eosinophilic gastroenteritis, and, in preliminary
studies, of ulcerative colitis.
These aims will further our long term objectives:
(1) Studying regulation of immune responses by IgG via FcGammaR, esp. the
effects of bovine IgG from dietary sources on human immune responses in
vitro and in vivo.
(2) Examine potential roles of bovine IgG and of human immune responses to
it in the pathogenesis of infantile colic, eosinophilic gastroenteritis,
and ulcerative colitis.
National Institute of Allergy and Infectious Diseases
CFDA Code
DUNS Number
068552207
UEI
L6NFUM28LQM5
Project Start Date
01-April-1987
Project End Date
31-March-1990
Budget Start Date
01-April-1988
Budget End Date
31-March-1989
Project Funding Information for 1988
Total Funding
$162,784
Direct Costs
$102,380
Indirect Costs
$60,404
Year
Funding IC
FY Total Cost by IC
1988
National Institute of Allergy and Infectious Diseases
$162,784
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01AI024005-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01AI024005-02
Patents
No Patents information available for 5R01AI024005-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01AI024005-02
Clinical Studies
No Clinical Studies information available for 5R01AI024005-02
News and More
Related News Releases
No news release information available for 5R01AI024005-02
History
No Historical information available for 5R01AI024005-02
Similar Projects
No Similar Projects information available for 5R01AI024005-02